TNIP2

Across TCGA pan-cancer cohorts, TNIP2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TNIP2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher TNIP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNIP2 expression acts as an unfavorable survival marker.

PRAD and UCEC are the cancer types where TNIP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TNIP2–PRAD (DFS)

Open the PRAD breakdown →